Switching from clopidogrel to prasugrel in patients having coronary stent implantation. (Q51151977)

31 March 2018

title

Switching from clopidogrel to prasugrel in patients having coronary stent implantation. (English)

1 reference

31 March 2018

1 reference

6

1 reference

31 March 2018

author name string

Guido Parodi

1

1 reference

31 March 2018

Giuseppe De Luca

2

1 reference

31 March 2018

Benedetta Bellandi

3

1 reference

31 March 2018

Vincenzo Comito

4

1 reference

31 March 2018

Renato Valenti

5

1 reference

31 March 2018

Nazario Carrabba

7

1 reference

31 March 2018

Angela Migliorini

8

1 reference

31 March 2018

R N Erica Ramazzotti

9

1 reference

31 March 2018

Gian Franco Gensini

10

1 reference

31 March 2018

Rosanna Abbate

11

1 reference

31 March 2018

David Antoniucci

12

1 reference

31 March 2018

publication date

1 October 2014

1 reference

31 March 2018

Journal of Thrombosis and Thrombolysis

published in

1 reference

31 March 2018

volume

38

1 reference

31 March 2018

issue

3

1 reference

31 March 2018

page(s)

395-401

1 reference

31 March 2018

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-1040-7

Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-1040-7

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-1040-7

Guidelines on myocardial revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-1040-7

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiogr

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-1040-7

Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocar

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-1040-7

Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-1040-7

Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a r

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-1040-7

High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-1040-7

Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-1040-7

High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-1040-7

Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-1040-7

The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-1040-7

Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-1040-7

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-1040-7

Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-1040-7

Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-1040-7

Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-1040-7

Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-1040-7

Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-1040-7

Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-013-1040-7

A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24659131

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reac

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24659131

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24659131

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11239-013-1040-7

1 reference

31 March 2018

1 reference

31 March 2018